Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The inactivated novel coronavirus vaccine (Vero cells) is a whole-virus, inactivated vaccine developed to prevent COVID-19. The active ingredient is an inactivated SARS-CoV‑2 virus, produced by culturing the virus on Vero cells—kidney epithelial cells from African green monkeys—followed by chemical or heat inactivation to eliminate infectivity while preserving antigenicity. The formulation includes an aluminum hydroxide adjuvant and standard excipients such as disodium hydrogen phosphate and sodium chloride. Upon intramuscular administration, the vaccine induces an immune response that generates neutralizing antibodies against SARS-CoV‑2, providing protection against COVID‑19. It is indicated for active immunization of adults and has demonstrated efficacy across multiple strains of the virus[1][2][3]. Multiple manufacturers produce this type of vaccine under different brand names.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated novel coronavirus vaccine (Vero cells).